Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Vaccination on Covid-19 Infection Symptoms in Multiple Sclerosis Patients Publisher



Sharifi P1 ; Rezaeimanesh N1 ; Moradi A2 ; Moghadasi AN1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Source: eNeurologicalSci Published:2024


Abstract

Background: Patients with multiple sclerosis (MS) are at higher risk of having infections due to receiving disease modifying therapies. The current study was conducted among Iranian MS patients who had experienced at least one episode of COVID-19 infection in order to evaluate the effects of COVID-19 vaccination on symptoms of their infection. Data on demographic information, MS characteristics, COVID-19 infection details, and vaccination status were collected. Statistical analyses, were performed to evaluate the association between vaccination and symptoms of COVID-19 infection. Methods: This cross-sectional study was conducted on confirmed MS patients. Demographic data and COVID-19 related symptoms were gathered via an online questionnaire. Confirmation of patients' who declared to be vaccinated was checked by their COVID-19 vaccination card. Results: A total of 236 MS patients participated in the study. The majority were female (79.7%), with a mean age of 36.1 ± 7.9 years. Among the participants, 72.5% had received the COVID-19 vaccine before their first episode of COVID-19 infection. The analysis showed a significant difference in the incidence of respiratory symptoms (P-value: 0.01) and headache (P-value: 0.04) between vaccinated and non-vaccinated individuals. Logistic regression analysis revealed that vaccinated MS patients had lower odds of developing respiratory symptoms (OR:0.29, 95% CI: 0.16 to 0.53, P-value<0.001) or headache (OR: 0.50, 95% CI: 0.25 to 0.98, P-value: 0.04) during their next COVID-19 infection episode. Moreover, MS patients who were receiving immunosuppressive drugs were less likely to have respiratory symptoms (OR:0.35, 95% CI: 0.16 to 0.77, P-value:0.009) but not headache (OR: 0.69, 95% CI: 0.30 to 1.60, P-value: 0.39). Conclusion: COVID-19 vaccination can reduce the incidence of respiratory symptoms and headaches in MS patients during COVID-19 infection episodes. Additionally, patients who are receiving immunosuppressive drugs may benefit from COVID-19 vaccination. © 2024 The Authors
Related Docs
View other Related Docs
1. Immunogenicity, Clinical Efficacy, and Safety of the Sinopharm (Bbibp-Corv) Sars-Cov-2 Vaccine Among People With Multiple Sclerosis Receiving Disease-Modifying Therapies: A Prospective Cohort Study, BMC Neurology (2024)
2. Multiple Sclerosis and Covid-19: A Retrospective Study in Iran, PLoS ONE (2023)
3. Effectiveness of Covid-19 Vaccines Against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies, Vaccines (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (13)
Nima Rezaei (10)
Other Related Docs
4. The Effectiveness of Covid-19 Vaccines in Reducing the Incidence, Hospitalization, and Mortality From Covid-19: A Systematic Review and Meta-Analysis, Frontiers in Public Health (2022)
5. Covid-19 Vaccinations: The Unknowns, Challenges, and Hopes, Journal of Medical Virology (2022)
6. Breakthrough Sars-Cov-2 Infections After Vaccination: A Critical Review, Human Vaccines and Immunotherapeutics (2022)
7. Risk of Flare or Relapse in Patients With Immune-Mediated Diseases Following Sars-Cov-2 Vaccination: A Systematic Review and Meta-Analysis, European Journal of Medical Research (2024)
8. Short-Term Sars-Cov-2 Re-Infection Rate in Vaccinated Health Workers Based on Received Vaccines: A Cross-Sectional Study, Current Respiratory Medicine Reviews (2023)
9. Association of Sars-Cov-2 Vaccination or Infection With Bell Palsy: A Systematic Review and Meta-Analysis, JAMA Otolaryngology - Head and Neck Surgery (2023)
10. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
11. Coronavirus Disease 2019 (Covid-19) in Pediatric Patients With Autoimmune Disorders, European Journal of Pediatrics (2023)
12. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
13. Sars-Cov-2 Mrna-Vaccine Candidate; Corenapcin®, Induces Robust Humoral and Cellular Immunity in Mice and Non-Human Primates, npj Vaccines (2022)
14. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
15. Cutaneous Adverse Reactions Following Covid-19 Vaccinations: A Systematic Review and Meta-Analysis, Journal of Cosmetic Dermatology (2022)
16. Association of Body Mass Index and Physical Activity With Fatigue, Depression, and Anxiety Among Iranian Patients With Multiple Sclerosis, Frontiers in Neurology (2023)
17. Multiple Sclerosis Projection in Tehran, Iran Using Bayesian Structural Time Series, BMC Neurology (2021)
18. Uncovering the Causal Link Between Obesity-Associated Genes and Multiple Sclerosis: A Systematic Literature Review, Brain and Behavior (2025)
19. Safety and Efficacy of Rcp Recombinant Spike Protein Covid-19 Vaccine Compared to Sinopharm Bbibp: A Phase Iii, Non-Inferiority Trial, Heliyon (2024)
20. The Effect of Crocin-Selenium Nanoparticles on the Cognition and Oxidative Stress Markers of Multiple Sclerosis Patients: A Randomized Triple-Blinded Placebo-Controlled Clinical Trial, BioMetals (2024)
21. The Patient-Reported Outcomes for the New Brand-Generic Teriflunomide in Relapsing-Remitting Multiple Sclerosis, Clinical Neurology and Neurosurgery (2024)
22. The Chimera of S1 and N Proteins of Sars-Cov-2: Can It Be a Potential Vaccine Candidate for Covid-19?, Expert Review of Vaccines (2022)
23. Safety and Immunogenicity of a Recombinant Receptor-Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against Covid-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial, Journal of Medical Virology (2023)
24. Covid-19 Vaccines Mix-And-Match: The Concept, the Efficacy and the Doubts, Journal of Medical Virology (2022)
25. A Comparison Between Sars-Cov-1 and Sars-Cov2: An Update on Current Covid-19 Vaccines, DARU# Journal of Pharmaceutical Sciences (2022)
26. Evaluation of Salivary Nitric Oxide Levels and Anxiety in Multiple Sclerosis Patients, With and Without Xerostomia: Correlation With Clinical Variables, BMC Oral Health (2025)
27. Seroconversion Following the First, Second, and Third Dose of Sars-Cov-2 Vaccines in Immunocompromised Population: A Systematic Review and Meta-Analysis, Virology Journal (2022)
28. Diagnostic Performance of a Novel Antigen-Capture Elisa for the Detection of Sars-Cov-2, Analytical Biochemistry (2023)
29. Incidence of Bell's Palsy After Coronavirus Disease (Covid-19) Vaccination: A Systematic Review and Meta-Analysis; [Incidencia De La Paralisis De Bell Despues De La Vacunacion Contra La Covid-19: Una Revision Sistematica Y Un Metanalisis], Neurologia (2024)
30. Clinical and Imaging Features of Familial and Sporadic Multiple Sclerosis, Caspian Journal of Neurological Sciences (2025)
31. Environmental Risk Factors of Late-Onset Multiple Sclerosis: A Population-Based Case-Control Study, Journal of Clinical Neuroscience (2025)
32. Multiple Sclerosis and Lower Urinary Tract Symptoms: A Survey of Prevalence, Characteristic and Urological Evaluations, SAGE Open Medicine (2023)
33. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
34. Investigation of the Safety of Live Attenuated Varicella-Zoster Virus Vaccination in Patients With Relapse-Remitting Multiple Sclerosis Treated With Natalizumab: A Case Series and Review of the Literature, Multiple Sclerosis and Related Disorders (2023)
35. Vlp-Based Covid-19 Vaccines: An Adaptable Technology Against the Threat of New Variants, Vaccines (2021)
36. Acute Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia Post Covid-19 Vaccination; a Systematic Review, Journal of the Neurological Sciences (2022)
37. The Effect of Covid-19 Mrna Vaccines Against Postvaccination Laboratory-Confirmed Sars-Cov-2 Infection, Symptomatic Covid-19 Infection, Hospitalization, and Mortality Rate: A Systematic Review and Meta-Analysis, Expert Review of Vaccines (2022)
38. Comparing Cognitive Impairment Using Macfims in Patients With Multiple Sclerosis and Healthy Controls: A Systematic Review and Meta-Analysis, BMC Neurology (2024)
39. Immunologic Response, Efficacy, and Safety of Vaccines Against Covid-19 Infection in Healthy and Immunosuppressed Children and Adolescents Aged 2 – 21 Years Old: A Systematic Review and Meta-Analysis, Journal of Clinical Virology (2022)
40. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
41. Safety and Immunogenicity of Corenapcin, a Sars-Cov-2 Mrna Vaccine, As a Fourth Heterologous Booster in Healthy Iranian Adults: A Double-Blind, Randomized, Placebo-Controlled, Phase 1 Clinical Trial With a Six-Month Follow-Up, International Immunopharmacology (2024)
42. A Case of Covid-19 Infection in a Kidney Transplant Recipient After Receiving the Single Dose of Covid-19 Vaccination, Annals of Medicine and Surgery (2022)
43. Potential Efficacy of Caffeine Ingestion on Balance and Mobility in Patients With Multiple Sclerosis: Preliminary Evidence From a Single-Arm Pilot Clinical Trial, PLoS ONE (2024)
44. Impact of Vaccination Status on Clinical Outcomes of Hospitalized Covid-19 Patients, BMC Infectious Diseases (2024)
45. Sudden Sensorineural Hearing Loss After Receiving an Inactivated Viral Vaccine, Sinopharm: Two-Case Report, SAGE Open Medical Case Reports (2023)
46. Aging & Covid-19 Susceptibility, Disease Severity, and Clinical Outcomes: The Role of Entangled Risk Factors, Experimental Gerontology (2021)
47. The Quest for a Better Fight: How Can Nanomaterials Address the Current Therapeutic and Diagnostic Obstacles in the Fight Against Covid-19?, Journal of Drug Delivery Science and Technology (2022)
48. Can Pulse Steroid Therapy Increase the Risk of Infection by Covid-19 in Patients With Multiple Sclerosis?, Clinical Neurology and Neurosurgery (2021)
49. Waterpipe and Cigarette Smoking and Drug and Alcohol Consumption, and the Risk of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Current Journal of Neurology (2023)
50. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)